TMCnet - World's Largest Communications and Technology Community



Research and Markets: PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022
[February 06, 2014]

Research and Markets: PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022" report to their offering.

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of Our 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

Strong uptake of branded and generic topical calcineurin inhibitors as well as systemic vitamin derivatives will be the key growth drivers, while prescribing behavior of Indian dermatologists from Our July 2013 survey suggests a highly crowded, genericized market.

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysilogy

3.2 Symptoms

4 Disease Management

4.1 Diagnosis

4.2 Treatment Overview

4.3 India

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

5.3 Product Profiles - Major Brands

5.3.1 Protopic (tacrolimus)

5.3.2 Elidel

5.3.3 Cyclosporine (numerous generic names)

5.3.4 Other Therapeutic Drug Classes Used in Atopic Dermatitis

6 Opportunity and Unmet Need

6.1 Overview

6.2 Unmet Needs

6.2.1 A Systemic Drug for Severe Recalcitrant Patients

6.2.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach

6.2.3 A Drug that Effectively Controls Patients' Pruritus

6.2.4 Further Research into the Pathophysiology of Atopic Dermatitis

6.2.5 A Drug that Induces Disease Remission

6.2.6 Improved Quality of Life for Both Patients and their Carers

6.3 Unmet Needs Gap Analysis

6.4 Opportunities

6.4.1 Increase Treatment Armamentarium for Severe Recalcitrant Patients

6.4.2 Predictive Tests for Patient Stratification

6.4.3 More Therapeutic Options that Address Patients' Pruritus

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Clinical Development

7.2.1 Phase II Pipeline Products

8 Market Outlook

8.1 Global Drivers and Barriers

8.1.1 Driver: Anticipated launch of the first biologic for the treatment of moderate to severe disease

8.1.2 Driver: The underserved severe refractory patient segment presents an untapped market opportunity

8.1.3 Driver: A drug that is able to target two or more atopic diseases would gain a foothold in these markets

8.1.4 Driver: Atopic dermatitis presents an attractive patient population for drug developers

8.1.5 Driver: Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents

8.1.6 Barrier: First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market

8.1.7 Barrier: The largest atopic dermatitis patient segment - mild disease - can be well-controlled on most forms of topical therapy

8.1.8 Barrier: Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products

8.1.9 Barrier: The complexity of the multiple etiologies that lead to atopic dermatitis means that treatment outcomes with existing drugs are not universal across all patient groups

8.1.10 Barrier: A significant proportion of patients experience disease remission in their early adolescent years and this may occur without drug therapy

8.2 India

9 Appendix

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy